Oct 19, 2023 7:00 am EDT Skye Bioscience to Host Virtual Investor Day on October 25, 2023: "CB1 Axis: Unlocking the Pharmaceutical Potential of the Endocannabinoid System"
Sep 27, 2023 7:00 am EDT Skye Bioscience Receives Clinical Site Approvals for Glaucoma Phase 2a Trial
Sep 5, 2023 7:00 am EDT Skye Bioscience to Present at H.C. Wainwright 25th Annual Global Investment Conference
Aug 21, 2023 7:00 am EDT Skye Completes $17M Financing and Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody
Aug 14, 2023 7:00 am EDT Skye Bioscience to Present at H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
Jul 13, 2023 7:00 am EDT Skye Bioscience Receives Positive Safety Review for Final Cohort of Fully-Enrolled Phase 1 Study of SBI-100 Ophthalmic Emulsion
Jul 6, 2023 7:00 am EDT Skye Bioscience Completes Production and Filling of Investigational Drug Material in Preparation for Phase 2a Glaucoma Clinical Trial
Jun 12, 2023 7:00 am EDT Skye Bioscience Completes Enrollment of Phase 1 Clinical Trial of Novel CB1R Agonist, SBI-100 Ophthalmic Emulsion